StreetAlpha.app
Home › Stocks › TRVI

Trevi Therapeutics, Inc. (TRVI)

Healthcare
$13.35
▼ −2.70%
LAST CLOSE · NOV 20

Trevi Therapeutics is developing Haduvio, an oral form of nalbuphine, as a treatment for chronic cough in lung disease patients. It last closed at $13.35 on Nov 20, down 2.70% on the day. The next earnings report for TRVI is expected around Tue, Mar 16, 2027, after the close. For the quarter ended Sep 2026, TRVI reported EPS of -$0.13. Over its last 8 reports the stock moved an average of 2.3% the session after earnings. Over the last 12 months TRVI insiders bought $0 of stock on the open market and sold $596K, according to SEC Form 4 filings.

AI Auto Pilots
Is TRVI in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TRVI.

Key Stats

Last 12 months
Results
Net income
−$60.8M
EPS (diluted)
−$0.40
Free cash flow
−$61.7M
Valuation
Market cap
$1.9B
142.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$27.8M
At Sep 30
Shareholder equity
$302.8M
Shares outstanding
142.6M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$33.9M−$33.9MFY2021FY2022: −$29.2M−$29.2MFY2022FY2023: −$29.1M−$29.1MFY2023FY2024: −$47.9M−$47.9MFY2024FY2025: −$42.8M−$42.8MFY2025

From TRVI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 16
Estimated date · After the close
Reported EPS
-$0.13
Quarter ended Sep 2026
Year ago EPS
-$0.08
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.11Dec '24Mar 2025: -$0.09Mar '25Jun 2025: -$0.09Jun '25Sep 2025: -$0.08Sep '25Dec 2025: -$0.06Dec '25Mar 2026: -$0.09Mar '26Jun 2026: -$0.11Jun '26Sep 2026: -$0.13Sep '26Latest -$0.13
Revenue by quarter
Not enough quarters on file yet.
How TRVI moved after its last 8 reports
Average move the session after a report ±2.3%
Nov 9, 2026After the close−2.6%
Aug 6, 2026After the close+0.1%
Apr 17, 2026Time not announced+4.8%
Mar 17, 2026After the close−4.5%
Nov 13, 2025After the close−0.8%
Aug 7, 2025After the close+1.6%
May 8, 2025After the close0.0%
Mar 18, 2025After the close+3.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on TRVIStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on TRVI
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on TRVI

Technical Analysis

TRVI · as of the Nov 20 close · updated each morning
Moving sideways

The stock is 3% below its 20 day and 3% below its 50 day average. It is 9% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 46). The nearest support is the swing low (Jun 3) at $13.25, and the nearest resistance the Pivot at $13.49.

Short trendNeutral
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 6.3%/day
Key levels
$20.2252 week high+51.5%
$15.77100 day average+18.1%
$14.75Swing high (May 27)+10.5%
$14.58200 day average+9.2%
$13.76Pivot R1+3.1%
$13.7520 day average+3.0%
$13.7350 day average+2.8%
$13.49Pivot+1.0%
$13.35Last close
$13.25Swing low (Jun 3)−0.7%
$13.09Pivot S1−1.9%
$9.8252 week low−26.4%
Indicators
RSI (14)46.25Middle of its rangeNeutral
MACD-0.03Below its signal lineBearish
Stochastic27.3Middle of its rangeNeutral
ADX (14)18.7No clear trend
Williams %R-79.2Oversold below −80, overbought above −20Neutral
CCI (20)-38.4Oversold below −100, overbought above 100Neutral
Rate of change−6.8%Change over 10 sessionsBearish
ATR (14)$0.85Typical daily range, 6.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for TRVI

What happened before

See how TRVI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow TRVI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How TRVI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for TRVIHow many large options trades hit TRVI, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

TRVI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲120 buying vs 87 selling
  • ●Held by funds +0.5 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding223218+2.3%
In funds' top 101012−16.7%
Held by funds106.1%105.6%+0.5 pts
New / increased36 / 8439 / 88−5.5%
Reduced / sold out56 / 3158 / 20+11.5%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See TRVI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

TRVI Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$596K1 sale · 1 insider
100% of the selling was under pre-arranged trading plans.
2026-09 sold $596KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 15Michael Thomas HeffernanDirectorSale plan39,473$15.09$596K
Mar 25, 2025Thomas SciasciaChief Scientific OfficerSale2,631$6.60$17K
Mar 21, 2025Jennifer L GoodPresident & CEOSale5,263$6.58$35K
Mar 10, 2025Farrell SimonChief Commercial OfficerSale plan81,313$6.75$549K
Every insider buy and sale for TRVI over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See TRVI insider trades →

From SEC Form 4 filings by TRVI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TRVI is in one of them and how their past TRVI trades turned out.

TRVI in the AI portfolios
Loading…

TRVI News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered TRVI in an article yet. Here's the latest on the wider market.

TRVI in the news

About Trevi Therapeutics

Trevi Therapeutics is a biopharmaceutical company based in New Haven, Connecticut, in the United States. It is developing Haduvio, an oral form of nalbuphine, as a treatment for chronic cough. The drug is in clinical trials for patients with idiopathic pulmonary fibrosis, other interstitial lung diseases, and refractory chronic cough. Nalbuphine has been used as an injectable pain medicine for decades, and the company holds worldwide commercial rights to Haduvio.

Headquarters
New Haven, CT